Patent intelligence · US
US 12297186
Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5
Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5
Patent details — US 12297186
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 13, 2025
- Expiration
- May 8, 2045
- Applicant
- AGOMAB SPAIN, S.L.U.
- Claims
- 34
- CPC classes
- A61K, A61K31/4709, A61K45/06, A61P
Quick answer
US 12297186 (Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5) is held by AGOMAB SPAIN, S.L.U.. Status: granted. Granted May 13, 2025. Expires May 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- AGOMAB SPAIN, S.L.U.
- Grant date
- Expiration
- Claims
- 34
- CPC classes
- A61K, A61K31/4709, A61K45/06, A61P, A61P35/00, A61P37/00
More from AGOMAB SPAIN, S.L.U.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12297186?
US 12297186 (Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor I/ALK5) is held by AGOMAB SPAIN, S.L.U.. Status: granted. Granted May 13, 2025. Expires May 8, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12297186?
AGOMAB SPAIN, S.L.U. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 12297186 expire?
Our index shows an expiration date of May 8, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.